DENV-2 subunit proteins fused to CR2 receptor-binding domain (P28)-induces specific and neutralizing antibodies to the Dengue virus in mice

References

• PAHO Dengue regional information: Number of cases. http://new.paho.org/hq/index.php?option=com_content&task=view&id=264&Itemid=363. PAHO (2011).
   Google Scholar
• Añez G, Morales-Betoulle ME, Rios M. Circulation of different lineages of dengue virus type 2 in Central America, their evolutionary time-scale and selection pressure analysis. PLoS One 2011; 6:e27459; http://dx.doi.org/10.1371/journal.pone.0027459; PMID: 22076162
   PubMed Web of Science ®Google Scholar
• Durbin AP, Whitehead SS. Next-generation dengue vaccines: novel strategies currently under development. Viruses 2011; 3:1800 - 14; http://dx.doi.org/10.3390/v3101800; PMID: 22069516
   PubMed Web of Science ®Google Scholar
• Heinz FX, Stiasny K. Flaviviruses and flavivirus vaccines. Vaccine 2012; 30:4301 - 6; http://dx.doi.org/10.1016/j.vaccine.2011.09.114; PMID: 22682286
   PubMed Web of Science ®Google Scholar
• Megret F, Hugnot JP, Falconar A, Gentry MK, Morens DM, Murray JM, et al. Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein. Virology 1992; 187:480 - 91; http://dx.doi.org/10.1016/0042-6822(92)90450-4; PMID: 1372140
   PubMed Web of Science ®Google Scholar
• Beasley DW, Barrett AD. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J Virol 2002; 76:13097 - 100; http://dx.doi.org/10.1128/JVI.76.24.13097-13100.2002; PMID: 12438639
   PubMed Web of Science ®Google Scholar
• Heinz FX, Stiasny K. Flaviviruses and their antigenic structure. J ClinVirol 2012; 55:289 - 95; http://dx.doi.org/10.1016/j.jcv.2012.08.024; PMID: 22999801
   PubMed Web of Science ®Google Scholar
• Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 2010; 8:271 - 83; http://dx.doi.org/10.1016/j.chom.2010.08.007; PMID: 20833378
   PubMed Web of Science ®Google Scholar
• Goncalvez AP, Purcell RH, Lai CJ. Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein. J Virol 2004; 78:12919 - 28; http://dx.doi.org/10.1128/JVI.78.23.12919-12928.2004; PMID: 15542644
   PubMed Web of Science ®Google Scholar
• Gollins SW, Porterfield JS. A new mechanism for the neutralization of enveloped viruses by antiviral antibody. Nature 1986; 321:244 - 6; http://dx.doi.org/10.1038/321244a0; PMID: 3713806
   PubMed Web of Science ®Google Scholar
• Crill WD, Roehrig JT. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 2001; 75:7769 - 73; http://dx.doi.org/10.1128/JVI.75.16.7769-7773.2001; PMID: 11462053
   PubMed Web of Science ®Google Scholar
• Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 2002; 108:717 - 25; http://dx.doi.org/10.1016/S0092-8674(02)00660-8; PMID: 11893341
   PubMed Web of Science ®Google Scholar
• Modis Y, Ogata S, Clements D, Harrison SC. Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol 2005; 79:1223 - 31; http://dx.doi.org/10.1128/JVI.79.2.1223-1231.2005; PMID: 15613349
   PubMed Web of Science ®Google Scholar
• Schieffelin JS, Costin JM, Nicholson CO, Orgeron NM, Fontaine KA, Isern S, et al. Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient. Virol J 2010; 7:28; http://dx.doi.org/10.1186/1743-422X-7-28; PMID: 20132551
   PubMed Web of Science ®Google Scholar
• Amorim JH, Diniz MO, Cariri FA, Rodrigues JF, Bizerra RS, Gonçalves AJ, et al. Protective immunity to DENV2 after immunization with a recombinant NS1 protein using a genetically detoxified heat-labile toxin as an adjuvant. Vaccine 2012; 30:837 - 45; http://dx.doi.org/10.1016/j.vaccine.2011.12.034; PMID: 22178517
   PubMed Web of Science ®Google Scholar
• Costa SM, Paes MV, Barreto DF, Pinhão AT, Barth OM, Queiroz JL, et al. Protection against dengue type 2 virus induced in mice immunized with a DNA plasmid encoding the non-structural 1 (NS1) gene fused to the tissue plasminogen activator signal sequence. Vaccine 2006; 24:195 - 205; http://dx.doi.org/10.1016/j.vaccine.2005.07.059; PMID: 16122850
   PubMed Web of Science ®Google Scholar
• Lu H, Xu XF, Gao N, Fan DY, Wang J, An J. Preliminary evaluation of DNA vaccine candidates encoding dengue-2 prM/E and NS1: their immunity and protective efficacy in mice. MolImmunol 2013; 54:109 - 14; http://dx.doi.org/10.1016/j.molimm.2012.11.007; PMID: 23270684
   PubMed Web of Science ®Google Scholar
• Zhang F, Ma W, Zhang L, Aasa-Chapman M, Zhang H. Expression of particulate-form of Japanese encephalitis virus envelope protein in a stably transfected Drosophila cell line. Virol J 2007; 4:17; http://dx.doi.org/10.1186/1743-422X-4-17; PMID: 17324254
   PubMed Web of Science ®Google Scholar
• Clements DE, Coller BA, Lieberman MM, Ogata S, Wang G, Harada KE, et al. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 2010; 28:2705 - 15; http://dx.doi.org/10.1016/j.vaccine.2010.01.022; PMID: 20097152
   PubMed Web of Science ®Google Scholar
• Coller BA, Clements DE, Bett AJ, Sagar SL, TerMeulen JH. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 2011; 29:7267 - 75; http://dx.doi.org/10.1016/j.vaccine.2011.07.021; PMID: 21777637
   PubMed Web of Science ®Google Scholar
• Block OK, Rodrigo WW, Quinn M, Jin X, Rose RC, Schlesinger JJ. A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice. Vaccine 2010; 28:8085 - 94; http://dx.doi.org/10.1016/j.vaccine.2010.10.004; PMID: 20959154
   PubMed Web of Science ®Google Scholar
• Hermida L, Rodríguez R, Lazo L, Silva R, Zulueta A, Chinea G, et al. A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. J Virol Methods 2004; 115:41 - 9; http://dx.doi.org/10.1016/j.jviromet.2003.09.024; PMID: 14656459
   PubMed Web of Science ®Google Scholar
• Srivastava AK, Putnak JR, Warren RL, Hoke CH Jr.. Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. Vaccine 1995; 13:1251 - 8; http://dx.doi.org/10.1016/0264-410X(94)00059-V; PMID: 8578812
   PubMed Web of Science ®Google Scholar
• Chen HW, Liu SJ, Li YS, Liu HH, Tsai JP, Chiang CY, et al. A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates. Arch Virol 2013; 158:1523 - 31; http://dx.doi.org/10.1007/s00705-013-1639-1; PMID: 23456422
   PubMed Web of Science ®Google Scholar
• Fearon DT, Carter RH. The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu Rev Immunol 1995; 13:127 - 49; http://dx.doi.org/10.1146/annurev.iy.13.040195.001015; PMID: 7542009
   PubMed Web of Science ®Google Scholar
• Carroll MC, Isenman DE. Regulation of humoral immunity by complement. Immunity 2012; 37:199 - 207; http://dx.doi.org/10.1016/j.immuni.2012.08.002; PMID: 22921118
   PubMed Web of Science ®Google Scholar
• Ross TM, Xu Y, Green TD, Montefiori DC, Robinson HL. Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. AIDS Res Hum Retroviruses 2001; 17:829 - 35; http://dx.doi.org/10.1089/088922201750252025; PMID: 11429124
   PubMed Web of Science ®Google Scholar
• Bower JF, Ross TM. A minimum CR2 binding domain of C3d enhances immunity following vaccination. AdvExp Med Biol 2006; 586:249 - 64; http://dx.doi.org/10.1007/0-387-34134-X_17; PMID: 16893077
   PubMed Web of Science ®Google Scholar
• Liu D, Wang J, Niu ZX. Contribution of Chinese Pekin duck complement component C3d-P29 repeats to enhancement of Th2-biased immune responses against NDV F gene induced by DNA immunization. ImmunopharmacolImmunotoxicol 2010; 32:297 - 306; http://dx.doi.org/10.3109/08923970903311802; PMID: 20148704
   PubMed Web of Science ®Google Scholar
• Dunn MD, Rossi SL, Carter DM, Vogt MR, Mehlhop E, Diamond MS, et al. Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice. Virol J 2010; 7:95; http://dx.doi.org/10.1186/1743-422X-7-95; PMID: 20462412
   PubMed Web of Science ®Google Scholar
• Roehrig JT. Antigenic structure of flavivirus proteins. Adv Virus Res 2003; 59:141 - 75; http://dx.doi.org/10.1016/S0065-3527(03)59005-4; PMID: 14696329
   PubMed Web of Science ®Google Scholar
• Chen Y, Maguire T, Marks RM. Demonstration of binding of dengue virus envelope protein to target cells. J Virol 1996; 70:8765 - 72; PMID: 8971005
   PubMed Web of Science ®Google Scholar
• Chen MC, Lin CF, Lei HY, Lin SC, Liu HS, Yeh TM, et al. Deletion of the C-terminal region of dengue virus nonstructural protein 1 (NS1) abolishes anti-NS1-mediated platelet dysfunction and bleeding tendency. J Immunol 2009; 183:1797 - 803; http://dx.doi.org/10.4049/jimmunol.0800672; PMID: 19592650
   PubMed Web of Science ®Google Scholar
• Mellado-Sánchez G, García-Machorro J, Sandoval-Montes C, Gutiérrez-Castañeda B, Rojo-Domínguez A, García-Cordero J, et al. A plasmid encoding parts of the dengue virus E and NS1 proteins induces an immune response in a mouse model. Arch Virol 2010; 155:847 - 56; http://dx.doi.org/10.1007/s00705-010-0652-x; PMID: 20390312
   PubMed Web of Science ®Google Scholar
• Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011; 29:7229 - 41; http://dx.doi.org/10.1016/j.vaccine.2011.06.094; PMID: 21745521
   PubMed Web of Science ®Google Scholar
• Robert Putnak J, Coller BA, Voss G, Vaughn DW, Clements D, Peters I, et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 2005; 23:4442 - 52; http://dx.doi.org/10.1016/j.vaccine.2005.03.042; PMID: 16005749
   PubMed Web of Science ®Google Scholar
• Zheng Q, Fan D, Gao N, Chen H, Wang J, Ming Y, et al. Evaluation of a DNA vaccine candidate expressing prM-E-NS1 antigens of dengue virus serotype 1 with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) in immunogenicity and protection. Vaccine 2011; 29:763 - 71; http://dx.doi.org/10.1016/j.vaccine.2010.11.014; PMID: 21095256
   PubMed Web of Science ®Google Scholar
• Hughes HR, Crill WD, Chang GJ. Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement. Virol J 2012; 9:115; http://dx.doi.org/10.1186/1743-422X-9-115; PMID: 22709350
   PubMed Web of Science ®Google Scholar
• Coconi-Linares N, Ortega-Dávila E, López-González M, García-Machorro J, García-Cordero J, Steinman RM, Cedillo-Barrón L, Gómez-Lim MA. Targeting of envelope domain III protein of DENV type 2 to DEC-205 receptor elicits neutralizing antibodies in mice. Vaccine 2013; 31:2366 - 71; http://dx.doi.org/10.1016/j.vaccine.2013.03.009; PMID: 23499580
   PubMed Web of Science ®Google Scholar
• Augusto EF, Moraes AM, Piccoli RA, Barral MF, Suazo CA, Tonso A, et al. Nomenclature and guideline to express the amount of a membrane protein synthesized in animal cells in view of bioprocess optimization and production monitoring. Biologicals 2010; 38:105 - 12; http://dx.doi.org/10.1016/j.biologicals.2009.07.005; PMID: 19699109
   PubMed Web of Science ®Google Scholar
• Lee Y, Haas KM, Gor DO, Ding X, Karp DR, Greenspan NS, et al. Complement component C3d-antigen complexes can either augment or inhibit B lymphocyte activation and humoral immunity in mice depending on the degree of CD21/CD19 complex engagement. J Immunol 2005; 175:8011 - 23; PMID: 16339538
   PubMed Web of Science ®Google Scholar
• Haspel N, Ricklin D, Geisbrecht BV, Kavraki LE, Lambris JD. Electrostatic contributions drive the interaction between Staphylococcus aureus protein Efb-C and its complement target C3d. Protein Sci 2008; 17:1894 - 906; http://dx.doi.org/10.1110/ps.036624.108; PMID: 18687868
   PubMed Web of Science ®Google Scholar
• Gor DO, Ding X, Li Q, Greenspan NS. Genetic fusion of three tandem copies of murine C3d sequences to diphtheria toxin fragment B elicits a decreased fragment B-specific antibody response. ImmunolLett 2006; 102:38 - 49; http://dx.doi.org/10.1016/j.imlet.2005.06.020; PMID: 16105692
   PubMed Web of Science ®Google Scholar
• Suradhat S, Braun RP, Lewis PJ, Babiuk LA, van DrunenLittel-van den Hurk S, Griebel PJ, et al. Fusion of C3d molecule with bovine rotavirus VP7 or bovine herpesvirus type 1 glycoprotein D inhibits immune responses following DNA immunization. Vet ImmunolImmunopathol 2001; 83:79 - 92; http://dx.doi.org/10.1016/S0165-2427(01)00369-5; PMID: 11604163
   PubMed Web of Science ®Google Scholar
• da Silva Voorham JM, Rodenhuis-Zybert IA, Ayala Nuñez NV, Colpitts TM, van der Ende-Metselaar H, Fikrig E, et al. Antibodies against the envelope glycoprotein promote infectivity of immature dengue virus serotype 2. PLoS One 2012; 7:e29957; http://dx.doi.org/10.1371/journal.pone.0029957; PMID: 22431958
   PubMed Web of Science ®Google Scholar
• de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. ProcNatlAcadSci U S A 2012; 109:7439 - 44; http://dx.doi.org/10.1073/pnas.1200566109; PMID: 22499787
   PubMed Web of Science ®Google Scholar
• Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, Sukupolvi-Petty S, et al. Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol 2006; 80:12149 - 59; http://dx.doi.org/10.1128/JVI.01732-06; PMID: 17035317
   PubMed Web of Science ®Google Scholar
• Costin JM, Zaitseva E, Kahle KM, Nicholson CO, Rowe DK, Graham AS, et al. Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop. J Virol 2013; 87:52 - 66; http://dx.doi.org/10.1128/JVI.02273-12; PMID: 23077306
   PubMed Web of Science ®Google Scholar
• Bustos-Arriaga J, García-Machorro J, León-Juárez M, García-Cordero J, Santos-Argumedo L, Flores-Romo L, et al. Activation of the innate immune response against DENV in normal non-transformed human fibroblasts. PLoSNegl Trop Dis 2011; 5:e1420; http://dx.doi.org/10.1371/journal.pntd.0001420; PMID: 22206025
   PubMed Web of Science ®Google Scholar
• Morens DM, Halstead SB, Repik PM, Putvatana R, Raybourne N. Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J ClinMicrobiol 1985; 22:250 - 4; PMID: 4031038
   PubMed Web of Science ®Google Scholar